| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 8 |
| 1 | METHYLPREDNISOLONE | 3 |
| 2 | MYCOPHENOLATE MOFETIL | 3 |
| 3 | PREDNISOLONE | 3 |
| 4 | PREDNISOLONE ORAL | 3 |
| 5 | PREDNISOLONE ORAL SOLUTION | 3 |
| 6 | TACROLIMUS | 3 |
| 7 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 3 |
| 8 | TACROLIMUS OINTMENT 0.1% | 3 |
| 9 | ANTI-THYMOCYTE GLOBULIN (RABBIT) | 2 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ELRANATAMAB-BCMM | 2 | 0.0017 |
| 1 | LISOCABTAGENE MARALEUCEL | 1 | 0.0011 |
| 2 | AMPICILLIN AND SULBACTAM | 1 | 0.0011 |
| 3 | EPCORITAMAB-BYSP | 1 | 0.0007 |
| 4 | TECLISTAMAB-CQYV | 1 | 0.0004 |
| 5 | AMPICILLIN SODIUM AND SULBACTAM SODIUM | 1 | 0.0004 |
| 6 | ANTI-THYMOCYTE GLOBULIN (RABBIT) | 2 | 0.0002 |
| 7 | CEFTAZIDIME | 1 | 0.0001 |
| 8 | AXICABTAGENE CILOLEUCEL | 1 | 0.0001 |
| 9 | HUMAN IMMUNOGLOBULIN G | 2 | 0.0001 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 1 | 0.0002 |
| 1 | CD19-directed Chimeric Antigen Receptor [EPC] | 1 | 0.0001 |
| 2 | Human Immunoglobulin G [EPC] | 2 | 0.0001 |
| 3 | Asparagine-specific Enzyme [EPC] | 1 | 0.0001 |
| 4 | Thrombopoietin Receptor Agonist [EPC] | 1 | 0.0001 |
| 5 | Complement Inhibitor [EPC] | 2 | 0.0000 |
| 6 | Penem Antibacterial [EPC] | 1 | 0.0000 |
| 7 | CD20-directed Cytolytic Antibody [EPC] | 8 | 0.0000 |
| 8 | Integrin Receptor Antagonist [EPC] | 2 | 0.0000 |
| 9 | Purine Antimetabolite [EPC] | 2 | 0.0000 |